Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
July 17, 2019

North America’s medical devices industry sees a rise of 11% in deal activity in Q2 2019

North America’s medical devices industry saw a rise of 11% in overall deal activity during Q2 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 253 deals worth $15.84bn were announced for the region during Q2 2019, against the last four-quarter average of 228 deals.

Of all the deal types, venture financing saw most activity in Q2 2019 with 189, representing a 74.7% share for the region.

In second place was M&A with 51 deals, followed by private equity deals with 13 transactions, respectively capturing a 20.2% and 5.1% share of the overall deal activity for the quarter.

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $13.56bn, while venture financing and private equity deals totalled $2.07bn and $211.19m, respectively.

North America medical devices industry deals in Q2 2019: Top deals

The top five medical devices deals accounted for 83.8% of the overall value during Q2 2019.

The combined value of the top five medical devices deals stood at $13.28bn, against the overall value of $15.84bn recorded for the quarter. The top announced medical devices deal tracked by GlobalData in Q2 2019 was 3M’s $6.73bn acquisition of Acelity.

In second place was the $5.8bn acquisition of Medidata Solutions by Dassault Systemes and in third place was Boston Scientific’s $465m acquisition of VertiFlex.

The $167.5m asset transaction with AngioDynamics by Medline Industries and Meridian Bioscience’s acquisition of GenePOC for $120m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.


Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy